PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdatePRNewsWire • 10/29/20
Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular AtrophyPRNewsWire • 10/21/20
Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental MilestonesPRNewsWire • 09/28/20
This Biotech Just Got A Key European Nod To Treat Rare Genetic DiseaseInvestors Business Daily • 08/17/20
PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and olderPRNewsWire • 08/07/20
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial ResultsPRNewsWire • 07/22/20
PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 MillionPRNewsWire • 07/20/20
PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular DystrophyPRNewsWire • 06/29/20
PTC Therapeutics to Commence Phase II/III Coronavirus Study in USZacks Investment Research • 06/18/20
PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19PRNewsWire • 06/17/20
PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular AtrophyPRNewsWire • 06/12/20
PTC Therapeutics (NASDAQ: PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 05/15/20
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/01/20